for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
The Medical Letter
   [6 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
     Published by The Medical Letter, Inc Homepage  [1 journal]   [SJR: 0.161]   [H-I: 15]
  • A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine
           Prevention - The Medical Letter
    • Authors: admin
      Abstract: August 18, 2014 - The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine prevention, it is available in Canada and Europe for treatment and prevention of migraines. A transcranial magnetic stimulation device (SpringTMS - eNeura Therapeutics) recently approved by the FDA for treatment of migraine preceded by aura will be reviewed in a future issue.
       
  • Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders - The Medical
           Letter
    • Authors: admin
      Abstract: August 18, 2014 - The FDA has approved an oral liquid formulation of glycerol phenylbutyrate (Ravicti – Hyperion) for chronic management of patients ≥2 years old with urea cycle disorders that cannot be adequately managed by a protein- restricted diet. Sodium phenylbutyrate (Buphenyl, and generics), another oral drug approved by the FDA for this indication, has a bitter taste. The new product, which contains no sodium, has little or no taste. Either drug must be used in addition to a protein-restricted diet and, if needed, dietary supplementation with amino acids and other nutrients.
       
  • Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia - The Medical
           Letter
    • Authors: admin
      Abstract: August 18, 2014 - Most patients with end-stage renal disease develop hyperphosphatemia, which can lead to secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality. The FDA has approved sucroferric oxyhydroxide (Velphoro – Fresenius Medical Care), a chewable phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the first iron-based phosphate binder to be approved for this indication.
       
  • Two New Drugs for Skin and Skin Structure Infections - The Medical Letter
    • Authors: admin
      Abstract: August 18, 2014 - The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future issue.
       
  • Adult Immunization - Treatment Guidelines
    • Authors: admin
      Abstract: June 1, 2014 - Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014